On March 17, the Chinese communist regime announced the identification of a dual infection of COVID-19 subtypes Omicron BA.5.2.48 and BF.7.14. The case was discovered in a patient who had exhibited symptoms such as poor appetite, fatigue, cough, chills, and fever between December 23, 2022, and February 12, 2023, and had tested positive for COVID-19 on December 29, 2022. The patient was admitted to two different hospitals in China, and upper respiratory samples collected from him on January 28 and February 7 showed traits of both subvariants, indicating he was infected with both simultaneously. This was the first recorded case of dual infection with both subtypes in China. The discovery has stirred online discussions among netizens with mixed reactions. Some were more concerned about the continued mutation of COVID-19 and urged everyone to stay vigilant, while others dismissed it as no big deal, suggesting that there are many new variants and no effective control measures in place. Meanwhile, some Chinese netizens have questioned whether the recent large-scale influenza A outbreak across mainland China could actually be a new mutant strain of COVID-19. Concerns remain about the accuracy and transparency of official data released by the Chinese regime.
China records first-ever case of two Omicron sub-variants co-infection.
